According to GlobalData’s company profile on Lipocine, Nanoparticle drug conjugates was a key innovation area identified from patents. Lipocine's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical composition for treating testosterone deficiency

A recently granted patent (Publication Number: US11872235B1) discloses a pharmaceutical composition containing a crystalline form of (17-ß)-3-Oxoandrost-4-en-17-yl tridecanoate with a melting point between 68-75°C. The composition, fully or partially dissolved in a lipophilic surfactant, includes the active ingredient in an amount ranging from 250 mg to about 350 mg. Additionally, the formulation may also contain a pharmaceutically acceptable carrier with a hydrophilic surfactant, such as polyethylene glycol, and can be presented in the form of a capsule or tablet.

Furthermore, the patent claims specify various formulations and release characteristics of the pharmaceutical composition. These include the use of specific lipophilic surfactants like fatty acids, monoglycerides, and diglycerides, as well as the release profile of the active ingredient over time. The compositions are designed to release a specific percentage of the (17-ß)-3-Oxoandrost-4-en-17-yl tridecanoate within defined time frames when tested under standardized conditions, ensuring optimal delivery and efficacy. The patent also highlights the use of these compositions in oral capsules for human administration, emphasizing the potential applications and benefits of this innovative pharmaceutical formulation.

To know more about GlobalData’s detailed insights on Lipocine, buy the report here.